Chronic kidney disease in long-term survivors of hematopoietic cell transplantation: Epidemiology, pathogenesis, and treatment
Chronic kidney disease in long-term survivors of hematopoietic cell transplantation: Epidemiology, pathogenesis, and treatment
复制标题
DOI：
10.1681/asn.2006020118
复制
发表时间：
2006-07-01
影响因子：
13.6
通讯作者：
Hingorani, Sangeeta
中科院分区：
文献类型：
--
作者：
Hingorani, Sangeeta
高剂量清髓性造血细胞移植正在成为一种越来越常见的治疗各种疾病的方式。患者生存可能受到大量治疗相关毒性的限制，包括慢性肾脏疾病（CKD）。虽然移植后的CKD大多数是特发性的，但血栓性微血管病综合征和肾病综合征也有描述。流行病学，发病机制，并为各种临床综合征与慢性肾脏病造血细胞移植患者的潜在治疗方案进行审查。随着全球范围内移植手术的适应症和数量的增加，CKD的负担也会增加。肾脏科医生和肿瘤科医生必须共同努力，及早识别有CKD风险的患者，以防止其发展和进展为终末期肾病。
High-dose myeloablative hematopoietic cell transplantation is becoming an increasingly common treatment modality for a variety of diseases. Patient survival may be limited by substantial treatment-related toxicities, including chronic kidney disease (CKD). Although the majority of CKD after transplantation is idiopathic, thrombotic microangiopathic syndromes and nephrotic syndrome have been described. Epidemiology, pathogenesis, and potential treatment options for the various clinical syndromes that are associated with CKD in hematopoietic cell transplantation patients is reviewed. As the indications for and the numbers of transplants that are performed worldwide increases, so will the burden of CKD. The nephrologists and oncologists will have to work together to identify patients who are at risk for CKD early to prevent its development and progression to end-stage kidney disease.